SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Zhang Liying)
 

Search: WFRF:(Zhang Liying) > The Movember Founda...

The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date

Bruinsma, Sophie M (author)
Erasmus University Medical Center
Zhang, Liying (author)
University of Toronto
Roobol, Monique J (author)
show more...
Bangma, Chris H (author)
Steyerberg, Ewout W (author)
Nieboer, Daan (author)
Van Hemelrijck, Mieke (author)
King's College London
Bjartell, Anders (creator_code:cre_t)
Lund University,Lunds universitet,Skåne University Hospital
show less...
 (creator_code:org_t)
 
2018-01-18
2018
English.
In: BJU International. - : Wiley. - 1464-4096. ; 121:5, s. 737-744
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database.PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time.RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing.CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Aged
Aged, 80 and over
Charities/organization & administration
Cohort Studies
Databases, Factual
Disease Progression
Early Detection of Cancer
Global Health
Humans
Male
Men's Health
Middle Aged
Prognosis
Prostatic Neoplasms/epidemiology
Public Health Surveillance
Risk Assessment
Time Factors
Time-to-Treatment
Watchful Waiting

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view